ARVN

Arvinas Inc

Add to Watchlist

Advanced Chart

6.490

+0.230(+3.670%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

6.625

Open

6.280

VWAP

6.37

Vol

1.94M

Mkt Cap

473.71M

Low

6.1601

Amount

12.37M

EV/EBITDA(TTM)

Total Shares

68.43M

-496.87M

EV/OCF(TTM)

P/S(TTM)

1.06

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

46.69M

-21.14%

-0.768

+21.87%

37.39M

-63.49%

-0.866

+27.41%

34.69M

-54.66%

-0.902

+84.05%

Estimates Revision

The market is revising Upward the revenue expectations for Arvinas, Inc. (ARVN) for FY2025, with the revenue forecasts being adjusted by 31.99% over the past three months. During the same period, the stock price has changed by -65.20%.

Revenue Estimates for FY2025

Revise Upward

+31.99%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-57.26%

In Past 3 Month

Stock Price

Go Down

-65.20%

In Past 3 Month

20 Analyst Rating

218.64% Upside

Wall Street analysts forecast ARVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARVN is 20.68 USD with a low forecast of 8.00 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

8 Hold

0 Sell

Moderate Buy

218.64% Upside

Current: 6.490

Low

8.00

Averages

20.68

High

74.00

218.64% Upside

Current: 6.490

Low

8.00

Averages

20.68

High

74.00

UBS

Eliana Merle

Strong Buy

Maintains

$74 → $21

2025-05-15

New

Reason

UBS

Eliana Merle

Price Target

$74 → $21

2025-05-15

New

Maintains

Strong Buy

Reason

Morgan Stanley

Terence Flynn

Hold

Maintains

$12 → $11

2025-05-09

Reason

Morgan Stanley

Terence Flynn

Price Target

$12 → $11

2025-05-09

Maintains

Hold

Reason

Jefferies

Akash Tewari

Strong Buy

Hold

Downgrades

$52 → $10

2025-05-02

Reason

Jefferies

Akash Tewari

Price Target

$52 → $10

2025-05-02

Downgrades

Strong Buy

Hold

Reason

Jefferies analyst Akash Tewari downgraded Arvinas to Hold from Buy with a price target of $10, down from $52.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$81 → $24

2025-05-02

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$81 → $24

2025-05-02

Maintains

Strong Buy

Reason

Barclays

Peter Lawson

Buy

Maintains

$32 → $16

2025-05-02

Reason

Barclays

Peter Lawson

Price Target

$32 → $16

2025-05-02

Maintains

Buy

Reason

Barclays lowered the firm's price target on Arvinas to $16 from $32 and keeps an Overweight rating on the shares. The firm says Pfizer reduced vepdeg development while the company's cash runway is extended to the second half of 2028 on workforce reduction. It has "further derisked" the model, but still sees upside.

Piper Sandler

Edward Tenthoff

Buy

Reiterates

$24 → $14

2025-05-02

Reason

Piper Sandler

Edward Tenthoff

Price Target

$24 → $14

2025-05-02

Reiterates

Buy

Reason

Piper Sandler lowered the firm's price target on Arvinas to $14 from $24 by removing vepdegestrant value, while keeping an Overweight rating on the shares. The firm notes the Phase III VERITAC-2 trial of vepdegestrant met the primary mPFS endpoint vs. fulvestrant in 2nd-line ESR1-mutant ER+/HER2- mBC patients, and Arvinas will present data at ASCO on May 31st. Arvinas and Pfizer will submit regulatory filings in the second half of 2025, which could lead to monotherapy approval in 2026, however will not initiate Phase III combo trials.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arvinas Inc (ARVN.O) is -1.73, compared to its 5-year average forward P/E of 76.61. For a more detailed relative valuation and DCF analysis to assess Arvinas Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

76.61

Current PE

-1.73

Overvalued PE

457.13

Undervalued PE

-303.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.17

Current EV/EBITDA

4.92

Overvalued EV/EBITDA

32.04

Undervalued EV/EBITDA

-62.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

28.10

Current PS

2.59

Overvalued PS

54.57

Undervalued PS

1.63

Financials

Annual

Quarterly

FY2025Q1

YoY :

+646.25%

188.80M

Total Revenue

FY2025Q1

YoY :

-185.71%

71.40M

Operating Profit

FY2025Q1

YoY :

-219.45%

82.90M

Net Income after Tax

FY2025Q1

YoY :

-217.53%

1.14

EPS - Diluted

FY2025Q1

YoY :

-8.50%

-89.30M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-88.14%

-59.22

FCF Margin - %

FY2025Q1

YoY :

-116.01%

43.91

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

74.4K

USD

3-6

Months

765.2K

USD

6-9

Months

6.4K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

565.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

1.0M

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.9M

Volume

Months

6-9

0.0

Volume

Months

0-12

2.3M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

74.4K

USD

3-6

Months

765.2K

USD

6-9

Months

6.4K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ARVN News & Events

Events Timeline

2025-05-01 (ET)

2025-05-01

14:12:22

Oppenheimer surprised by 'hasty' decision to cull frontline Vepdeg development

2025-05-01

07:07:36

Arvinas reports Q1 EPS $1.14 vs (97c) last year

2025-04-28 (ET)

2025-04-28

06:49:25

Arvinas reports data from preclinical combination studies of ARV-393

News

7.0

05-13Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

7.0

05-12PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

7.0

05-09Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

People Also Watch

Two Harbors Investment Corp

Employers Holdings Inc

Apogee Enterprises Inc

ANI Pharmaceuticals Inc

CRA International Inc

Hertz Global Holdings Inc

FAQ

What is Arvinas Inc (ARVN) stock price today?

The current price of ARVN is 6.49 USD — it has increased 3.67 % in the last trading day.

ARVN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ARVN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Arvinas Inc (ARVN) stock price today?

What is Arvinas Inc (ARVN)'s business?

What is the price predicton of ARVN Stock?

What is Arvinas Inc (ARVN)'s revenue for the last quarter?

What is Arvinas Inc (ARVN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Arvinas Inc (ARVN)'s fundamentals?

How many employees does Arvinas Inc (ARVN). have?

What is Arvinas Inc (ARVN) market cap?